Tags

Type your tag names separated by a space and hit enter

Formulation and in vitro/in vivo investigation of carbamazepine controlled-release matrix tablets.
Pharmazie. 1999 Feb; 54(2):139-41.P

Abstract

Carbamazepine controlled-release tablet formulations containing hydroxypropyl methylcellulose (HPMC) as matrix material at different concentrations were developed and evaluated in vitro and in vivo. The formulation containing 10% HPMC (HPMC-10) showed a controlled-release profile comparable to that of a commercially available, controlled-release carbamazepine preparation (Tegretol CR 200). The kinetics of controlled-release carbamazepine tablets was examined in eight healthy volunteers. The peak plasma concentration of 1.99 +/- 0.56 micrograms.ml-1 was obtained for HPMC-10 at 15.0 +/- 9.0 h, and 1.33 +/- 0.35 micrograms.ml-1 for Tegretol CR 200 at 15.2 +/- 8.9 h, and AUC0-infinity values of 85.2 +/- 30.8 micrograms.h.ml-1 and 76.9 +/- 20.7 micrograms.h.ml-1, respectively. Developed formulation (HPMC-10) was found to be bioequivalent to Tegretol CR 200 and, controlled release was obtained with smoother concentration-time curve resulting in less fluctuations.

Authors+Show Affiliations

Hacettepe University, Faculty of Pharmacy, Ankara, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10084159

Citation

Ikinci, G, et al. "Formulation and in Vitro/in Vivo Investigation of Carbamazepine Controlled-release Matrix Tablets." Die Pharmazie, vol. 54, no. 2, 1999, pp. 139-41.
Ikinci G, Capan Y, Senel S, et al. Formulation and in vitro/in vivo investigation of carbamazepine controlled-release matrix tablets. Pharmazie. 1999;54(2):139-41.
Ikinci, G., Capan, Y., Senel, S., Dalkara, T., & Hincal, A. A. (1999). Formulation and in vitro/in vivo investigation of carbamazepine controlled-release matrix tablets. Die Pharmazie, 54(2), 139-41.
Ikinci G, et al. Formulation and in Vitro/in Vivo Investigation of Carbamazepine Controlled-release Matrix Tablets. Pharmazie. 1999;54(2):139-41. PubMed PMID: 10084159.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Formulation and in vitro/in vivo investigation of carbamazepine controlled-release matrix tablets. AU - Ikinci,G, AU - Capan,Y, AU - Senel,S, AU - Dalkara,T, AU - Hincal,A A, PY - 1999/3/20/pubmed PY - 1999/3/20/medline PY - 1999/3/20/entrez SP - 139 EP - 41 JF - Die Pharmazie JO - Pharmazie VL - 54 IS - 2 N2 - Carbamazepine controlled-release tablet formulations containing hydroxypropyl methylcellulose (HPMC) as matrix material at different concentrations were developed and evaluated in vitro and in vivo. The formulation containing 10% HPMC (HPMC-10) showed a controlled-release profile comparable to that of a commercially available, controlled-release carbamazepine preparation (Tegretol CR 200). The kinetics of controlled-release carbamazepine tablets was examined in eight healthy volunteers. The peak plasma concentration of 1.99 +/- 0.56 micrograms.ml-1 was obtained for HPMC-10 at 15.0 +/- 9.0 h, and 1.33 +/- 0.35 micrograms.ml-1 for Tegretol CR 200 at 15.2 +/- 8.9 h, and AUC0-infinity values of 85.2 +/- 30.8 micrograms.h.ml-1 and 76.9 +/- 20.7 micrograms.h.ml-1, respectively. Developed formulation (HPMC-10) was found to be bioequivalent to Tegretol CR 200 and, controlled release was obtained with smoother concentration-time curve resulting in less fluctuations. SN - 0031-7144 UR - https://www.unboundmedicine.com/medline/citation/10084159/Formulation_and_in_vitro/in_vivo_investigation_of_carbamazepine_controlled_release_matrix_tablets_ DB - PRIME DP - Unbound Medicine ER -